[8-K] Grace Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Grace Therapeutics reported securing approximately $4.0 million in cash proceeds from recent exercises of common warrants originally issued in a September 2023 private placement.

The Company also disclosed that 1,190,927 of those common warrants have expired, as the 60th day after the U.S. Food and Drug Administration’s acceptance for review of the Company’s New Drug Application for GTx-104 has passed. GTx-104 is a clinical-stage, injectable formulation of nimodipine being developed for I.V. infusion to address unmet needs in aneurysmal subarachnoid hemorrhage.

Insights

Biotech capital markets analyst

Cash inflow from warrant exercises; remaining 1.19M warrants expired.

Grace Therapeutics received approximately $4.0 million from the exercise of previously issued common warrants. This represents cash raised without entering a new financing agreement, using existing investor options.

The Company noted that 1,190,927 common warrants from the 2023 private placement have expired after the 60th day following FDA acceptance for review of the NDA for GTx-104. The expiration removes those instruments from potential future exercises, while the cash received supports operations.

Further details, including any timing for additional milestones tied to GTx-104, were not included in the excerpt. Subsequent disclosures may provide updates on development progress and capital position.

false0001444192NASDAQ00014441922025-10-232025-10-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2025

GRACE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-35776	98-1359336
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

103 Carnegie Center
Suite 300
Princeton, New Jersey (Address of Principal Executive Offices) 08540 (Zip Code)

Registrant’s telephone number, including area code: (609) 322-1602

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	GRCE	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 8.01. Other Events.

On October 23, 2025, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously issued in a private placement that the Company closed in September 2023. The remaining 1,190,927 common warrants issued in the 2023 private placement have expired as the 60th day after the U.S. Food and Drug Administration’s acceptance for review of the Company’s New Drug Application for GTx-104 has passed. GTx-104 is a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage patients.

A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit		Description
99.1		Press Release, dated October 23, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			GRACE THERAPEUTICS, INC.
Date:	October 23, 2025	By:	/s/ Prashant Kohli
			Prashant Kohli
			Chief Executive Officer

FAQ

How much funding did GRCE secure from warrant exercises?

Grace Therapeutics secured approximately $4.0 million from exercises of previously issued common warrants.

What happened to the remaining warrants from GRCE’s 2023 private placement?

A total of 1,190,927 common warrants have expired after the 60th day following FDA acceptance for review of the NDA for GTx-104.

What is GTx-104 mentioned by GRCE?

GTx-104 is a clinical-stage, novel injectable formulation of nimodipine for I.V. infusion targeting aneurysmal subarachnoid hemorrhage.

What triggered the expiration of GRCE’s remaining warrants?

The expiration occurred after the 60th day following the FDA’s acceptance for review of GRCE’s NDA for GTx-104.

Did Grace Therapeutics provide details about a new financing deal?

No new financing deal was described; the cash was raised through exercises of existing common warrants.

Where can I find more information on this GRCE update?

The Company issued a press release attached as Exhibit 99.1 providing additional details.